Research and development of new AI-powered tech is causing a major overhaul in the healthcare sector, with experts both optimistic and horrified at the same time. Analysts at market.us are forecasting the global AI in healthcare market to hit nearly $700 billion by 2034, growing at an explosive 38.5% CAGR along the way. With new technologies getting closer to full FDA approval, now one of the biggest hurdles for AI in healthcare is gaining the trust of clinicians and patients alike, all while proving efficacy of these new solutions. From an investment standpoint, the opportunity is enormous, with the market paying closer attention to AI roll outs and the developers behind them, including Avant Technologies, Inc. (OTCQB: AVAI), RadNet, Inc. (NASDAQ: RDNT), Clover Health Investments, Corp. (NASDAQ: CLOV), Tevogen Bio Holdings Inc. (NASDAQ: TVGN), and Butterfly Network, Inc. (NYSE: BFLY).

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended June 30, 2025.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finderopens in a new tab, a first-of-its-kind generative AI tool developed with Amazon Web Services (AWS). Designed to simplify lab test selection, Test Finder enables healthcare providers to ask questions or describe conditions in plain language and receive curated test recommendations—enhancing the user experience and freeing up more time for patient care.

The 23rd China International In Vitro Diagnostic Expo by CACLP and its concurrent activities will return from 21–23 March 2026, at the Xiamen International Expo Center in Fujian Province, China.

VieCure Inc., pioneer of an intelligent cancer care ecosystem that democratizes precision oncology for community-based practices, today announced a strategic partnership with Guardant Health to embed Guardant's next-generation sequencing (NGS)-based precision oncology tests into the VieCure Halo Intelligence platform. The integration represents the latest expansion of VieCure's AI-based, scalable, and accessible technology, embedding critical testing required for patient diagnosis and advanced treatment.

Noul said it has signed a memorandum of understanding (MOU) with Seegene Brazil to introduce its AI-based cervical cancer diagnostic solution, miLab CER, to the Brazilian market.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for AISight® Dx*—its digital pathology image management system—for use in primary diagnosis in clinical settings. Building on the initial 510(k) clearance for AISight Dx(Novo) in 2022, this latest milestone underscores the platform’s continuous innovation and PathAI’s commitment to delivering enhanced capabilities as the product evolves.

Microsoft has built an artificial intelligence-powered medical tool it claims is four times more successful than human doctors at diagnosing complex ailments, as the tech giant unveils research it believes could speed up treatment.

Paige, a leader in next-generation AI technology, and the Breast International Group (BIG), a leading international non-profit organization dedicated to breast cancer research, today announced a new partnership to conduct collaborative research aimed at improving breast cancer diagnosis, treatment, and patient outcomes.